- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
21st Century Cures Brings Hope for Rare Disease Research
However, not everyone supports the bill's provisions that promote the development of pediatric rare disease drugs through the "voucher" incentive.
The 21st Century Cures bill, which was unanimously approved by a House panel just a few weeks back, brings promise of faster drug development, and also offers hope to the rare disease advocacy groups. The bill includes provision to extend the "voucher" program for companies developing treatments for pediatric rare diseases.
Approximately 15 million children are diagnosed with rare diseases, which can result in nearly 35% of deaths in the first year of life.
Pharmaceutical companies are often cautious about venturing into the world of rare diseases for several reasons: fear of potential negative outcomes, limited returns, increased stringency with clinical trials in children, etc. Therefore, to motivate the pharmaceutical industry to invest efforts in developing theses drugs, the Congress initiated a voucher program in 2011 which allows the company to have another one of their drugs approved quicker than usual. The company can also sell this voucher if they so desire.
The Cures bill is seeking an extension on this voucher program, which is scheduled to expire next year.
However, not everyone is happy with this program. Read more at Kaiser Health News: http://bit.ly/1KXbSvK
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
